Revisiting phage therapy: new applications for old resources.
暂无分享,去创建一个
Franklin L. Nobrega | Ana Rita Costa | Joana Azeredo | A. R. Costa | L. Kluskens | J. Azeredo | Franklin L Nobrega | Leon D Kluskens
[1] S. Abedon,et al. Phage therapy pharmacology phage cocktails. , 2012, Advances in applied microbiology.
[2] V. Fischetti,et al. Bacteriophage lysins as effective antibacterials. , 2008, Current opinion in microbiology.
[3] M. Momol,et al. Phage therapy for plant disease control. , 2010, Current pharmaceutical biotechnology.
[4] K. Murphy. The λ gam protein inhibits RecBCD binding to dsDNA ends , 2007 .
[5] A. Henein. What are the limitations on the wider therapeutic use of phage? , 2013, Bacteriophage.
[6] Jeffrey E. Barrick,et al. Bacteriophages use an expanded genetic code on evolutionary paths to higher fitness , 2014, Nature chemical biology.
[7] C. Rm. Phage therapy: past history and future prospects. , 1999 .
[8] S. Abedon,et al. Phage therapy in clinical practice: treatment of human infections. , 2010, Current pharmaceutical biotechnology.
[9] F. D'Herelle. On an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr. F. D'Herelle, presented by Mr. Roux. 1917. , 2007, Research in microbiology.
[10] K. Miyanaga,et al. Alteration of tail fiber protein gp38 enables T2 phage to infect Escherichia coli O157:H7. , 2005, Journal of biotechnology.
[11] N. Cook,et al. The crystal structure of lambda-Gam protein suggests a model for RecBCD inhibition. , 2007, Journal of molecular biology.
[12] S. Abedon,et al. Bacteriophage host range and bacterial resistance. , 2010, Advances in applied microbiology.
[13] J. Dolan,et al. Use of Genetically Engineered Phage To Deliver Antimicrobial Agents to Bacteria: an Alternative Therapy for Treatment of Bacterial Infections , 2003, Antimicrobial Agents and Chemotherapy.
[14] Łusiak-SzelachowskaMarzanna,et al. Phage neutralization by sera of patients receiving phage therapy. , 2014 .
[15] U. Qimron,et al. Efficient engineering of a bacteriophage genome using the type I-E CRISPR-Cas system , 2014, RNA biology.
[16] Chad W. Euler,et al. Synergism between a Novel Chimeric Lysin and Oxacillin Protects against Infection by Methicillin-Resistant Staphylococcus aureus , 2010, Antimicrobial Agents and Chemotherapy.
[17] M. Clokie,et al. Clostridium difficile phages: still difficult? , 2014, Front. Microbiol..
[18] S. Abedon,et al. Phage cocktails and the future of phage therapy. , 2013, Future microbiology.
[19] Xiaomei Zhou,et al. Identification and analysis of recombineering functions from Gram-negative and Gram-positive bacteria and their phages , 2008, Proceedings of the National Academy of Sciences.
[20] Eric C. Keen. Phage Therapy: Concept to Cure , 2012, Front. Microbio..
[21] B. Wanner,et al. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[22] Frank Buchholz,et al. A new logic for DNA engineering using recombination in Escherichia coli , 1998, Nature Genetics.
[23] C. Merril,et al. An amino acid substitution in a capsid protein enhances phage survival in mouse circulatory system more than a 1000-fold. , 2005, Virus research.
[24] L. Goodridge. Designing phage therapeutics. , 2010, Current pharmaceutical biotechnology.
[25] R. Carlton,et al. Phage therapy: past history and future prospects. , 1999, Archivum immunologiae et therapiae experimentalis.
[26] W. Hardt,et al. PEGylation of bacteriophages increases blood circulation time and reduces T‐helper type 1 immune response , 2008, Microbial biotechnology.
[27] H. Brüssow. What is needed for phage therapy to become a reality in Western medicine? , 2012, Virology.
[28] Timothy K Lu,et al. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy , 2009, Proceedings of the National Academy of Sciences.
[29] Mahmoud Y. Alkawareek,et al. Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro. , 2012, FEMS immunology and medical microbiology.
[30] K. Miyanaga,et al. Toward rational control of Escherichia coli O157:H7 by a phage cocktail , 2004, Applied Microbiology and Biotechnology.
[31] C. Sassetti,et al. Mycobacterial recombineering. , 2015, Methods in molecular biology.
[32] M. Cotten,et al. Transferrin-polycation-DNA complexes: the effect of polycations on the structure of the complex and DNA delivery to cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[33] J. Behr,et al. High-efficiency transfection of primary human keratinocytes with positively charged lipopolyamine:DNA complexes. , 1994, The Journal of investigative dermatology.
[34] S. Cartinhour,et al. Recombineering Using RecTE from Pseudomonas syringae , 2010, Applied and Environmental Microbiology.
[35] S. Reardon. Phage therapy gets revitalized , 2014, Nature.
[36] W. Han,et al. A Method for Generation Phage Cocktail with Great Therapeutic Potential , 2012, PloS one.
[37] Remo Guidieri. Res , 1995, RES: Anthropology and Aesthetics.
[38] D. Hilbert,et al. Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model. , 2005, Surgery.
[39] Tamás Fehér,et al. Bacteriophage recombineering in the lytic state using the lambda red recombinases , 2012, Microbial biotechnology.
[40] U. Bläsi,et al. Therapy of Experimental Pseudomonas Infections with a Nonreplicating Genetically Modified Phage , 2004, Antimicrobial Agents and Chemotherapy.
[41] W. Fortuna,et al. Phage neutralization by sera of patients receiving phage therapy. , 2014, Viral immunology.
[42] D. Helinski,et al. Contained use of Bacteriophages: Risk Assessment and Biosafety Recommendations , 2010 .
[43] J. Klumpp,et al. Endolysins as antimicrobials. , 2012, Advances in virus research.
[44] Jan Borysowski,et al. Bacteriophage Endolysins as a Novel Class of Antibacterial Agents , 2006, Experimental biology and medicine.
[45] V. Fischetti,et al. Bacteriophage lytic enzymes: novel anti-infectives. , 2005, Trends in microbiology.
[46] J. Gill,et al. Phage choice, isolation, and preparation for phage therapy. , 2010, Current pharmaceutical biotechnology.
[47] H. Krisch,et al. Phage-Antibiotic Synergy (PAS): β-Lactam and Quinolone Antibiotics Stimulate Virulent Phage Growth , 2007, PloS one.
[48] M. Gottesman,et al. Characterization of bacteriophage lambda reverse as an Escherichia coli phage carrying a unique set of host-derived recombination functions. , 1974, Journal of molecular biology.
[49] S. Moineau,et al. CRISPR-Cas: an efficient tool for genome engineering of virulent bacteriophages , 2014, Nucleic acids research.
[50] M. Loessner,et al. Bacteriophage endolysins as novel antimicrobials. , 2012, Future microbiology.
[51] C. Merril,et al. Long-circulating bacteriophage as antibacterial agents. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[52] E. Vandamme. Phage therapy and phage control: to be revisited urgently!! , 2014 .
[53] S. Abedon,et al. Pros and cons of phage therapy , 2011, Bacteriophage.
[54] M. Piuri,et al. Recombineering , 2012, Bacteriophage.
[55] Sylvain Moineau,et al. Bacteriophage resistance mechanisms , 2010, Nature Reviews Microbiology.
[56] M. Piuri,et al. BRED: A Simple and Powerful Tool for Constructing Mutant and Recombinant Bacteriophage Genomes , 2008, PloS one.
[57] I. Huys,et al. Taking Bacteriophage Therapy Seriously: A Moral Argument , 2014, BioMed research international.
[58] H. Ackermann. Frequency of morphological phage descriptions in the year 2000 , 2001, Archives of Virology.
[59] J. Norris,et al. Prokaryotic gene therapy to combat multidrug resistant bacterial infection , 2000, Gene Therapy.
[60] James J. Collins,et al. Dispersing biofilms with engineered enzymatic bacteriophage , 2007, Proceedings of the National Academy of Sciences.
[61] C. Merril,et al. Escherichia coli K1's Capsule Is a Barrier to Bacteriophage T7 , 2005, Applied and Environmental Microbiology.
[62] Rob Lavigne,et al. Learning from Bacteriophages - Advantages and Limitations of Phage and Phage-Encoded Protein Applications , 2012, Current protein & peptide science.
[63] Juan A Hermoso,et al. Taking aim on bacterial pathogens: from phage therapy to enzybiotics. , 2007, Current opinion in microbiology.
[64] Anni-Maria Örmälä,et al. Phage therapy , 2013, Bacteriophage.